@article{df764cbb0ed24a198ddff6c8a50a48c3,
title = "Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib",
keywords = "BTK inhibitors, CLL, Efficacy, Next-generation BTK inhibitors, Resistance, Side effects, Toxicity",
author = "Masa Lasica and Tam, \{Constantine S.\}",
note = "Funding Information: Dr M. Lasica declares no conflict of interest. Prof C.S. Tam receives honoraria from Janssen, AbbVie, Beigene, Eli Lilly and AstraZeneca, and his institution receives research funding from Janssen and AbbVie .",
year = "2021",
month = aug,
doi = "10.1016/j.hoc.2021.03.006",
language = "English",
volume = "35",
pages = "761--773",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "Elsevier",
number = "4",
}